Drug Profile
Research programme: Trk receptor antagonists - AstraZeneca
Alternative Names: AZ-23; AZ-64Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 02 Sep 2009 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)